Compugen (NASDAQ:CGEN) Issues Quarterly Earnings Results

Compugen (NASDAQ:CGEN) issued its earnings results on Tuesday. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.21 by ($0.20), Zacks reports. Compugen had a return on equity of 2.61% and a net margin of 2.67%. The business had revenue of $17.13 million for the quarter, compared to analysts’ expectations of $17.67 million. During the same period last year, the company posted ($0.11) earnings per share.

Compugen Stock Performance

NASDAQ:CGEN traded down $0.01 during mid-day trading on Wednesday, hitting $1.59. 262,108 shares of the company’s stock traded hands, compared to its average volume of 406,589. The company has a market cap of $141.89 million, a PE ratio of 80.50 and a beta of 2.64. The firm’s 50 day simple moving average is $1.77 and its 200 day simple moving average is $1.88. Compugen has a 1 year low of $0.55 and a 1 year high of $3.03.

Wall Street Analyst Weigh In

Separately, StockNews.com raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.